期刊文献+

抗BAFF单克隆抗体轻链和重链可变区基因的克隆及鉴定

Cloning and identification of the variable region gene of mouse anti-human BAFF mAb
下载PDF
导出
摘要 目的:在本实验室成功制备小鼠抗人BAFF单克隆抗体的基础上,通过分子克隆方法获得该抗体可变区基因序列。方法:从1株小鼠抗人BAFF单克隆抗体杂交瘤细胞FMMUB4中提取总RNA,以此为模版反转录成cDNA,用针对小鼠单克隆抗体重链和轻链可变区基因序列的特异性引物分别进行PCR反应,PCR产物连接入载体,经筛选阳性克隆、酶切鉴定后送测序,测序结果进行生物信息学分析。结果:成功克隆了抗BAFF单克隆抗体FMMUB4重链和轻链可变区基因,测序结果证实序列正确。结论:获得了抗BAFF单克隆抗体FMMUB4重链和轻链可变区基因序列,为下一步构建相关基因工程抗体打下良好基础。 AIM: To obtain the variable region gene sequence of heavy and light chain of mouse anti-human BAFF monoclonal antibody (mAb) on base of BAFF mAb which was cloned in our laboratory. METHODS: The total RNA was extracted from mouse anti-human BAFF mAb hybridoma cell line FMMUB4, and then the RNA was reverse tran- scribed into cDNA. Specific primers were designed to amplify the targeted gene. The targeted gene fragments were inserted into vectors to construct the clone vectors. The gene sequences were analyzed after identified by positive clones screening and restrictive enzyme digestion. RESULTS: The variable region gene sequences of mouse anti-human BAFF mAb were obtained. CONCLUSION: The variable region gene sequences of mouse anti-human BAFF mAb will provide experimental basis for further study on constructing engineered antibodies.
出处 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2012年第1期49-52,共4页 Chinese Journal of Cellular and Molecular Immunology
基金 国家自然科学基金资助项目(30972683) 陕西省攻关计划(2010K12-02-06) 第四军医大学学员课外科研课题(08865-01)
关键词 BAFF 单克隆抗体 重链可变区基因 基因克隆 BAFF mAb variable region of heavy and light chain gene cloning
  • 相关文献

参考文献12

  • 1Yang J, Pospisil R, Ray S, et al. Investigations of a rabbit ( Oryctolagus cuniculus) model of systemic lupus erythematosus (SLE), BAFF and its receptors[J]. PLoS One, 2009, 4( 12): e8494.
  • 2Zhou L, Zhong RQ , Hao WY, et al. lnterleukin-10 and interferon-3, up-regulate the expression of B-cell activating factor in cultured human promyelocytic leukemia cells[ J]. Exp tool pathol, 2009, 87( 1 ) : 54 -58.
  • 3Krivosikova M, Dallos T, Maslinski W, et al. B cell activating factor, its role in autoimmunity, and targeting in autoimmune diseases[ J]. Bratisl Lek,isty, 2009, 110(3) : 137 -45.
  • 4Mariette X , Roux S , Zhang J , et al. The level of Blys (BAFF) cor- relates with the titre of autoantibodies in human Sjogren's syndrome [J]. Ann Rheum Dis , 2003, 62(2): 168-171.
  • 5Liu K, Chandra M. Altered B-cell signaling in lupus[ J]. Autoimmu Rev, 2008, 48 : 1568 -9972.
  • 6Miossec P, Verweij CL, Klareskog L, et al. Biomarkers and person- alised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies [ J ]. Ann Rheum Dis, 2011, 70(10) : 1713 -1718.
  • 7Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gpl30 signaling[ J]. Clin Invest, 2011, 121 (9) : 3375 -3383.
  • 8Sun J, Lin Z, Feng J, et al. BAFF-targeting therapy, a promising strategy for treating autoimmune diseases[ J]. Eur J Pharmacol, 2005, 3:1-5.
  • 9Cao M, Cao P, Yan P, et al. Construction, Purification, and Characterization of Anti-BAFF scFv-Fc Fusion Antibody Expressed in CHO/dhfr-Cells [ J ]. Appl Biochem Biotechnol, 2008, 157 : 562 - 74.
  • 10Furie R, Stohl W, Ginzler EM, et al. Biologic actlvlty and satety oI belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus[ J]. Arthritis Res Ther, 2008, 10 : 1186 - 2506.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部